Evaluation of the effects of VKORC1 polymorphisms and haplotypes, CYP2C9 genotypes, and clinical factors on warfarin response in Sudanese patients
Open Access
- 18 May 2011
- journal article
- Published by Springer Science and Business Media LLC in European Journal of Clinical Pharmacology
- Vol. 67 (11), 1119-1130
- https://doi.org/10.1007/s00228-011-1060-1
Abstract
African populations, including the Sudanese, are underrepresented in warfarin pharmacogenetic studies. We designed a study to determine the associations between the polymorphisms and haplotype structures of CYP2C9 and VKORC1 and warfarin dose response in Sudanese patients, one of the most genetically diverse populations in Africa. The effect of the CYP2C9 polymorphisms (*2, *3, *5, *6, *8, *9, and *11), 20 VKORC1 tag SNPs and haplotypes, and clinical covariates were comprehensively assessed in 203 Sudanese warfarin-treated patients. Patients with the CYP2C9*2,*5,*6, or *11 variant required a daily warfarin dose that was 21% lower than those with CYP2C9*1/*1 (4.7 vs 5.8 mg/day, P < 0.001). SNPs around the VKORC1 and POL3S genes were divided into two haplotype blocks in Sudanese populations. According to multiple linear regression results, rs8050984, rs7294, and rs7199949 in the VKORC1 and POL3S genes (P CYP2C9 genotype (*2, *5, *6, *11; P < 0.001), body weight (P = 0.04), target INR (P = 0.007), and concurrent medications (P = 0.029) could explain about 36.7% of the total warfarin dose variation. Our data revealed that VKORC1 and CYP2C9 polymorphisms are important factors that influence warfarin dose response in Sudanese patients. Our data suggest that combinations of the SNPs may improve predictions of warfarin dose requirements.Keywords
This publication has 48 references indexed in Scilit:
- New genetic variant that might improve warfarin dose prediction in African AmericansBritish Journal of Clinical Pharmacology, 2010
- Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groupsBlood, 2010
- The Genetic Structure and History of Africans and African AmericansScience, 2009
- A potentially deleterious new CYP2C9 polymorphism identified in an African American patient with major hemorrhage on warfarin therapyBlood Cells, Molecules, and Diseases, 2009
- A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin DosePLoS Genetics, 2009
- Estimation of the Warfarin Dose with Clinical and Pharmacogenetic DataThe New England Journal of Medicine, 2009
- VKORC1 Polymorphisms, Haplotypes and Haplotype Groups on Warfarin Dose Among African–Americans and European–AmericansPharmacogenomics, 2008
- Dosing Algorithms to Predict Warfarin Maintenance Dose in Caucasians and African AmericansClinical Pharmacology & Therapeutics, 2008
- Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of WarfarinClinical Pharmacology & Therapeutics, 2008
- Genetic-based dosing in orthopedic patients beginning warfarin therapyBlood, 2007